title: Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts.
abstract: Mitomycin C (MMC), a chemotherapeutic agent in breast cancer treatments, inhibits tumor growth through DNA cross-linking and breaking, but it has severe side effects. Here we examined whether and how curcumin reduced the side effects of MMC. We found that combination treatment with MMC and curcumin reduced tumor weight by 70% and 36% compared with saline and curcumin-treated groups, respectively. The combination treatment reduced weight loss and improved kidney function and bone marrow suppression compared with MMC treatment alone. Moreover, the combination treatment inhibited glucose regulatory protein (GRP58)-mediated DNA cross-linking. The combination treatment inhibited GRP58 through the ERK/p38 MAPK pathway. In conclusion, the current study provided evidence that MMC and curcumin combination treatment reduced MMC side effects by inhibiting GRP58-mediated DNA cross-linking through the ERK/p38 MAPK pathway.
authors.affiliation: Research Center for Traditional Chinese Medicine Complexity System, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
authors.forename: Qian-Mei
authors.initials: QM
authors.lastname: Zhou
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Yi-Yu
authors.initials: YY
authors.lastname: Lu
authors.forename: Xiu-Feng
authors.initials: XF
authors.lastname: Wang
authors.forename: Shi-Bing
authors.initials: SB
authors.lastname: Su
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D045744:Cell Line, Tumor; D003432:Cross-Linking Reagents / Q000009:adverse effects*; D003474:Curcumin / Q000627:therapeutic use*; D004247:DNA / Q000737:chemistry / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000502:physiology; D005260:Female; D006801:Humans; D020935:MAP Kinase Signaling System; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D016685:Mitomycin / Q000009:adverse effects*; D009368:Neoplasm Transplantation; D019704:Protein Disulfide-Isomerases / Q000037:antagonists & inhibitors*; D014183:Transplantation, Heterologous; D048051:p38 Mitogen-Activated Protein Kinases / Q000502:physiology
chemical_list: D000903:Antibiotics, Antineoplastic; D003432:Cross-Linking Reagents; D016685:Mitomycin; D004247:DNA; D048049:Extracellular Signal-Regulated MAP Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C513195:Pdia3 protein, mouse; D019704:Protein Disulfide-Isomerases; D003474:Curcumin
references.citation: Cancer Lett. 2007 Oct 8;255(2):170-81
references.pmid: 17448598
references.citation: Cancer Invest. 2007 Apr-May;25(3):135-9
references.pmid: 17530482
references.citation: JOP. 2008 May 08;9(3):305-8
references.pmid: 18469443
references.citation: Science. 1994 Aug 5;265(5173):808-11
references.pmid: 7914033
references.citation: Mol Cancer Ther. 2007 Oct;6(10):2719-27
references.pmid: 17938265
references.citation: Pharmacol Res. 2001 Feb;43(2):145-50
references.pmid: 11243715
references.citation: EMBO J. 2002 Jun 3;21(11):2655-63
references.pmid: 12032078
references.citation: Science. 1995 Nov 24;270(5240):1326-31
references.pmid: 7481820
references.citation: J Clin Oncol. 1998 Oct;16(10):3335-44
references.pmid: 9779710
references.citation: Pharmacol Res. 1999 Mar;39(3):175-9
references.pmid: 10094841
references.citation: Eur J Cancer Clin Oncol. 1987 Feb;23(2):195-9
references.pmid: 3127216
references.citation: Chem Biol Interact. 2006 Jul 25;162(1):81-87
references.pmid: 16806134
references.citation: Clin Exp Metastasis. 2003;20(6):499-505
references.pmid: 14598883
references.citation: Cancer Res. 2004 Jun 1;64(11):3940-8
references.pmid: 15173006
references.citation: Cancer. 2004 Jul 1;101(1):3-27
references.pmid: 15221985
references.citation: Future Oncol. 2005 Jun;1(3):405-14
references.pmid: 16556014
references.citation: Cancer Res. 2003 Sep 15;63(18):6016-25
references.pmid: 14522930
references.citation: J Cell Biochem. 1999 Mar 15;72(4):528-39
references.pmid: 10022612
references.citation: Br J Cancer. 2000 Apr;82(7):1305-11
references.pmid: 10755406
references.citation: Int J Cancer. 1996 Jan 17;65(2):263-71
references.pmid: 8567127
references.citation: Cancer Invest. 2009 Jul;27(6):624-35
references.pmid: 19283527
references.citation: Eur J Cancer. 2005 Jun;41(9):1331-8
references.pmid: 15869876
references.citation: Adv Cancer Res. 1998;74:49-139
references.pmid: 9561267
references.citation: J Cell Biochem. 2002;85(2):325-33
references.pmid: 11948688
references.citation: J Natl Cancer Inst. 2008 Oct 1;100(19):1352-60
references.pmid: 18812552
references.citation: Mol Cell Biol. 1999 Apr;19(4):2435-44
references.pmid: 10082509
references.citation: Anticancer Drugs. 2003 Jun;14(5):341-6
references.pmid: 12782939
references.citation: Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1429-35
references.pmid: 17692474
references.citation: Nature. 1994 Dec 22-29;372(6508):739-46
references.pmid: 7997261
references.citation: Cancer Sci. 2009 Mar;100(3):389-95
references.pmid: 19154413
references.citation: Breast Cancer Res. 2001;3(3):150-3
references.pmid: 11305949